Service de Réanimation médicale, Hôpital Pellegrin
Bordeaux, Aquitaine, 33000, France
NCT Number: NCT01932814
The purpose of the present study is to determine whether administration of aminoglycosides in septic critically ill patient is a risk factor for acute kidney injury
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Bordeaux, Aquitaine, 33000, France
Severe sepsis and septic shock despite recent advances in surviving sepsis campaign remain encumbered by a high mortality rate close to 30%. One cornerstone of the management of these patients remains the early and appropriate antibiotic administration, , which must be also active at the site of infection. Aminoglycosides are often administered in combination with beta lactams in this context . According to the progress in pharmacokinetic management achieved over the past decade, their safety and efficiency tended to increase but many uncertainties remain. The purpose of the present study is to determine whether administration of aminoglycosides in septic critically ill patient is a risk factor for acute kidney injury.
Study design: This is an open retrospective monocentric cohort study including septic critically ill patients from november 2008 to january 2010. To determine the incidence and the specific risk of nephrotoxicity of aminoglycosides, only hospitalized patients without initial acute kidney injury or with rapidly improving kidney function during the three first days will be included.Primary outcome will be the occurrence of acute kidney injury assessed with the RIFLE classification (Risk, Injury, Failure, Loss, and End-stage kidney disease) from day 4 to day 15. Patients receiving aminoglycosides will be compared with a control group, i.e. not receiving them. We estimated hazard ratios (HR) and 95% confidence intervals (CI) with adjusted and propensity score (PS)-matched Cox-proportional hazards models.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: between day 4 and day 15
Time frame: between day 1and day 3
Time frame: between day 4 and day 15
Time frame: between day 1 to day 6
daily dose, peak serum concentration, through level serum concentration
Université Victor Segalen Bordeaux 2
Other
Retrospective Analysis of Aminoglycoside-associated Acute Renal Injury in Septic Critically Ill Patients
Acronym: REAMICHOC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02034240
Acute Kidney Injury, Female Urogenital Diseases
Kolding, Denmark
View Trial DetailsNCT03628300
Acute Kidney Injury, Beta Lactams
Amiens, France
View Trial DetailsNCT05900284
Acute Kidney Injury, Female Urogenital Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06498336
Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
Ostrava, Moravian-Silesian Region, Czechia
View Trial Details